BC Week In Review | Jun 1, 2015
Clinical News

Alpelisib: Phase I data

Data from 6 evaluable previously treated patients with HER2-positive metastatic breast cancer in an open-label, dose-escalation, U.S. Phase I trial showed that once-daily oral alpelisib plus once-weekly 20 mg/kg IV LJM716 and Herceptin trastuzumab led...
BC Week In Review | Jun 1, 2015
Clinical News

LJM716: Phase I data

Data from 6 evaluable previously treated patients with HER2-positive metastatic breast cancer in an open-label, dose-escalation, U.S. Phase I trial showed that once-daily oral alpelisib plus once-weekly 20 mg/kg IV LJM716 and Herceptin trastuzumab led...
BC Innovations | Jun 6, 2013
Cover Story

Driving cancer through ErbB3

Roche 's Genentech Inc. unit has shown that mutations in ERBB3 can drive oncogenesis by enhancing the receptor's ability to form a heterodimer with HER2 . 1 Because the process appears to depend on HER2, the...
Items per page:
1 - 3 of 3